Neurofibromatosis type 2.

Area of Science:

• Genetics
• Oncology
• Neurology

Background:

• Neurofibromatosis type 2 (NF2) is an autosomal-dominant inherited tumor predisposition syndrome.
• Caused by mutations in the NF2 gene on chromosome 22.
• Characterized by schwannomas on cranial and spinal nerves, leading to hearing loss, deafness, meningiomas, and ependymomas.

Purpose of the Study:

• To review the genetic basis, clinical manifestations, and management strategies for Neurofibromatosis type 2.
• To highlight the challenges in diagnosis and treatment.
• To discuss emerging therapeutic approaches.

Main Methods:

• Literature review of genetic mutations, clinical features, and treatment outcomes for NF2.
• Analysis of mutation types (truncating vs. exon deletions) and their correlation with disease severity.
• Overview of current management including surgery, watchful waiting, radiation, and novel drug therapies.

Main Results:

• Truncating mutations are frequent germline events causing severe NF2, while exon deletions are associated with milder forms.
• Over 50% of patients have de novo mutations, and up to 33% exhibit mosaicism.
• Surgery is the primary treatment, with radiation and watchful waiting playing roles.

Conclusions:

• NF2 presents significant management challenges, impacting morbidity and life expectancy.
• Effective genetic analysis strategies are crucial for sensitive detection, especially for exon deletions.
• Emerging targeted drug therapies offer potential for substantial improvements in managing this devastating condition.